VAL Stock Overview
A biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
ValiRx plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.029 |
52 Week High | UK£0.15 |
52 Week Low | UK£0.018 |
Beta | 0.64 |
1 Month Change | -9.23% |
3 Month Change | -27.16% |
1 Year Change | -68.11% |
3 Year Change | -85.06% |
5 Year Change | -91.42% |
Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
VAL | GB Biotechs | GB Market | |
---|---|---|---|
7D | 2.4% | -0.7% | -0.6% |
1Y | -68.1% | -21.0% | 6.4% |
Return vs Industry: VAL underperformed the UK Biotechs industry which returned -21% over the past year.
Return vs Market: VAL underperformed the UK Market which returned 6.4% over the past year.
Price Volatility
VAL volatility | |
---|---|
VAL Average Weekly Movement | 27.9% |
Biotechs Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VAL's share price has been volatile over the past 3 months.
Volatility Over Time: VAL's weekly volatility has increased from 18% to 28% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 8 | Suzy Dilly | www.valirx.com |
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company’s lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19.
ValiRx plc Fundamentals Summary
VAL fundamental statistics | |
---|---|
Market cap | UK£3.90m |
Earnings (TTM) | -UK£2.04m |
Revenue (TTM) | UK£9.60k |
406.7x
P/S Ratio-1.9x
P/E RatioIs VAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VAL income statement (TTM) | |
---|---|
Revenue | UK£9.60k |
Cost of Revenue | UK£1.44k |
Gross Profit | UK£8.16k |
Other Expenses | UK£2.05m |
Earnings | -UK£2.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.015 |
Gross Margin | 85.00% |
Net Profit Margin | -21,226.05% |
Debt/Equity Ratio | 0.8% |
How did VAL perform over the long term?
See historical performance and comparison